U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146906) titled 'A Study to Assess the Effects of Zigakibart on IgA Nephropathy.' on Aug. 21.

Brief Summary: The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Study Start Date: Nov. 18, 2025

Study Type: INTERVENTIONAL

Condition: Immunoglobulin A Nephropathy (IgAN)

Intervention: BIOLOGICAL: zigakibart

zigakibart 600 mg sc injections every second week for 104 weeks (2 years)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Published by HT Digital Content Services with permission from Health Daily Digest....